サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：降圧剤の世界市場 - 産業分析、市場規模・シェア・成長・動向・予測 (2022年～2031年)
市場調査レポート
商品コード
1110422

降圧剤の世界市場 - 産業分析、市場規模・シェア・成長・動向・予測 (2022年～2031年)

Antihypertensive Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 213 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.46円
降圧剤の世界市場 - 産業分析、市場規模・シェア・成長・動向・予測 (2022年～2031年)
出版日: 2022年06月09日
発行: Transparency Market Research
ページ情報: 英文 213 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の降圧剤の市場について分析し、過去・現在の成長動向と市場機会、今後の市場指標と考察 (2022年～2031年)、市場収益の動向 (2017年～2031年)、世界市場のCAGRの見通し (2022年～2031年) などを調査しております。

目次

第1章 序文

第2章 前提と調査手法

第3章 エグゼクティブサマリー：世界の降圧剤市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • 世界の降圧剤市場の分析と予測 (2017年～2031年)
    • 市場収益の予測 (単位：10億米ドル)

第5章 市場の見通し

  • 業界の主な動向
  • 影響シナリオ
  • 新製品の開発

第6章 世界の降圧剤市場：市場規模の予測、治療薬の種類別 (単位：10億米ドル)

  • イントロダクションと定義
  • 市場規模の予測：治療薬の種類別 (2017年～2031年)
    • 利尿薬
    • アンギオテンシン変換酵素阻害剤
    • アンギオテンシン受容体遮断薬
    • βブロッカー
    • 血管拡張剤
    • カルシウムチャネル遮断薬
    • レニン阻害剤
    • αブロッカー
    • その他
  • 世界の降圧剤市場の魅力：治療薬の種類別

第7章 世界の降圧剤市場：市場規模の予測、種類別 (単位：10億米ドル)

  • イントロダクションと定義
  • 市場規模の予測：種類別 (2017年～2031年)
    • 原発性高血圧
    • 二次性高血圧
  • 世界の降圧剤市場の魅力：種類別

第8章 世界の降圧剤市場：市場規模の予測、薬物療法の種類別 (単位：10億米ドル)

  • イントロダクション
  • 市場規模の予測：薬物療法の種類別 (2017年～2031年)
    • 単剤療法
    • 併用療法
    • 多剤混合薬
  • 世界の降圧剤市場の魅力：薬物療法の種類別

第9章 世界の降圧剤市場：市場規模の予測、流通チャネル別 (単位：10億米ドル)

  • イントロダクション
  • 市場規模の予測：流通チャネル別 (2017年～2031年)
    • 小売薬局
    • 病院薬局
    • オンライン薬局
    • その他
  • 世界の降圧剤市場の魅力：流通チャネル別

第10章 世界の降圧剤市場：市場規模の予測、地域別 (単位：10億米ドル)

  • イントロダクション
  • 市場規模の予測：地域別 (2017年～2031年)
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 世界の降圧剤市場の魅力：地域別

第11章 北米の降圧剤市場の分析と予測

  • イントロダクション
  • 市場規模の予測：治療薬の種類別 (2017年～2031年)
  • 市場規模の予測：種類別 (2017年～2031年)
  • 市場規模の予測：薬物療法の種類別 (2017年～2031年)
  • 市場規模の予測：流通チャネル別 (2017年～2031年)
  • 市場規模の予測：国別/サブ地域別 (2017年～2031年)
    • 米国
    • カナダ
  • 北米の降圧剤市場の魅力分析

第12章 欧州の降圧剤市場の分析と予測

第13章 アジア太平洋の降圧剤市場の分析と予測

第14章 ラテンアメリカの降圧剤市場の分析と予測

第15章 中東・アフリカの降圧剤市場の分析と予測

第16章 競合情勢

  • 市場参入企業：競合マトリックス (階層別・企業規模別)
  • 企業プロファイル
    • Pfizer, Inc.
    • Sanofi SA
    • Novartis AG
    • Boehringer Ingelheim GmbH
    • Actelion Ltd. (Johnson &Johnson Services, Inc.)
    • F. Hoffmann-La Roche Ltd.
    • Bayer AG
    • Daiichi Sankyo Company, Limited
    • Takeda Pharmaceutical Company Limited
図表

List of Tables

  • Table 01: Global Antihypertensive Drugs Market Size (US$ Bn) Forecast, by Therapy Type, 2017-2031
  • Table 02: Global Antihypertensive Drugs Market Size (US$ Bn) Forecast, by Diuretics, 2017-2031
  • Table 03: Global Antihypertensive Drugs Market Size (US$ Bn) Forecast, by Beta-blockers, 2017-2031
  • Table 04: Global Antihypertensive Drugs Market Size (US$ Bn) Forecast, by Type, 2017-2031
  • Table 05: Global Antihypertensive Drugs Market Size (US$ Bn) Forecast, by Medication Type, 2017-2031
  • Table 06: Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031
  • Table 07: Global Antihypertensive Drugs Value (US$ Bn) Forecast, by Region, 2017-2031
  • Table 08: North America Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Country, 2017-2031
  • Table 09: North America Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Therapy Type, 2017-2031
  • Table 10: North America Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Diuretics, 2017-2031
  • Table 11: North America Antihypertensive Drugs Market Size (US$ Bn) Forecast, by Beta-blockers, 2017-2031
  • Table 12: North America Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Type, 2017-2031
  • Table 13: North America Antihypertensive Drugs Market Size (US$ Bn) Forecast, by Medication Type, 2017-2031
  • Table 14: North America Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031
  • Table 15: Europe Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 16: Europe Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Therapy Type, 2017-2031
  • Table 17: Europe Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Diuretics, 2017-2031
  • Table 18: Europe Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Beta-blockers, 2017-2031
  • Table 19: Europe Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Type, 2017-2031
  • Table 20: Europe Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Medication Type, 2017-2031
  • Table 21: Europe Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031
  • Table 22: Asia Pacific Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 23: Asia Pacific Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Therapy Type, 2017-2031
  • Table 24: Asia Pacific Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Diuretics, 2017-2031
  • Table 25: Asia Pacific Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Beta-blockers, 2017-2031
  • Table 26: Asia Pacific Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Type, 2017-2031
  • Table 27: Asia Pacific Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Medication Type, 2017-2031
  • Table 28: Asia Pacific Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031
  • Table 29: Latin America Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 30: Latin America Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Therapy Type, 2017-2031
  • Table 31: Latin America Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Diuretics, 2017-2031
  • Table 32: Latin America Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Beta-blockers, 2017-2031
  • Table 33: Latin America Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Type, 2017-2031
  • Table 34: Latin America Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Medication Type, 2017-2031
  • Table 35: Latin America Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031
  • Table 36: Middle East & Africa Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 37: Middle East & Africa Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Therapy Type, 2017-2031
  • Table 38: Middle East & Africa Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Diuretics, 2017-2031
  • Table 39: Middle East & Africa Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Beta-blockers, 2017-2031
  • Table 40: Middle East & Africa Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Type, 2017-2031
  • Table 41: Middle East & Africa Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Medication Type, 2017-2031
  • Table 42: Middle East & Africa Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global Antihypertensive Drugs Market Size Value (US$ Bn) Forecast, 2017-2031
  • Figure 02: Global Antihypertensive Drugs Market Value Share (%), by Therapy Type, 2017-2031
  • Figure 03: Global Antihypertensive Drugs Market Value Share (%), by Type, 2017-2031
  • Figure 04: Global Antihypertensive Drugs Market Value Share (%), by Distribution Channel, 2017-2031
  • Figure 05: Global Antihypertensive Drugs Market Value Share (%), by Distribution Channel, 2017-2031
  • Figure 06: Global Antihypertensive Drugs Market Value Share Analysis, by Therapy Type, 2017-2031
  • Figure 07: Global Antihypertensive Drugs Market Attractiveness Analysis, by Therapy Type, 2017-2031
  • Figure 08: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Diuretics, 2017-2031
  • Figure 09: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Angiotensin Converting Enzyme Inhibitors, 2017-2031
  • Figure 10: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Angiotensin Receptor Blockers, 2017-2031
  • Figure 11: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Beta-blockers, 2017-2031
  • Figure 12: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Vasodilators, 2017-2031
  • Figure 13 : Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Calcium Channel Blockers, 2017-2031
  • Figure 14: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Renin Inhibitors, 2017-2031
  • Figure 15: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Alpha-blockers, 2017-2031
  • Figure 16: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Others, 2017-2031
  • Figure 17: Global Antihypertensive Drugs Market Value Share Analysis, by Type, 2017-2031
  • Figure 18: Global Antihypertensive Drugs Market Attractiveness Analysis, by Type, 2017-2031
  • Figure 19: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Primary Hypertension, 2017-2031
  • Figure 20: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Secondary Hypertension, 2017-2031
  • Figure 21: Global Antihypertensive Drugs Market Value Share Analysis, by Medication Type, 2017-2031
  • Figure 22: Global Antihypertensive Drugs Market Attractiveness Analysis, by Medication Type, 2017-2031
  • Figure 23: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Monotherapy, 2017-2031
  • Figure 24: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Combination Therapy, 2017-2031
  • Figure 25: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Fixed Dose Combinations, 2017-2031
  • Figure 26: Global Antihypertensive Drugs Market Value Share Analysis, by Distribution Channel, 2017-2031
  • Figure 27: Global Antihypertensive Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031
  • Figure 28: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017-2031
  • Figure 29: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017-2031
  • Figure 30: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Online Pharmacies, 2017-2031
  • Figure 31: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Others, 2017-2031
  • Figure 32: Global Antihypertensive Drugs Value Share, by Region, 2017-2031
  • Figure 33: Global Antihypertensive Drugs Attractiveness, by Region, 2017-2031
  • Figure 34: North America Antihypertensive Drugs Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031
  • Figure 35: North America Antihypertensive Drugs Market Value Share Analysis, by Country, 2017-2031
  • Figure 36: North America Antihypertensive Drugs Market Attractiveness Analysis, by Country, 2017-2031
  • Figure 38: North America Antihypertensive Drugs Market Value Share Analysis, by Therapy Type, 2017-2031
  • Figure 39: North America Antihypertensive Drugs Market Attractiveness Analysis, by Therapy Type, 2017-2031
  • Figure 40: North America Antihypertensive Drugs Market Value Share Analysis, by Type, 2017-2031
  • Figure 41: North America Antihypertensive Drugs Market Attractiveness Analysis, by Type, 2017-2031
  • Figure 42: North America Antihypertensive Drugs Market Value Share Analysis, by Medication Type, 2017-2031
  • Figure 43: North America Antihypertensive Drugs Market Attractiveness Analysis, by Medication Type, 2017-2031
  • Figure 44: North America Antihypertensive Drugs Market Value Share Analysis, by Distribution Channel, 2017-2031
  • Figure 45: North America Antihypertensive Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031
  • Figure 46: Europe Antihypertensive Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 47: Europe Antihypertensive Drugs Market Value Share Analysis, by Country/Sub-region, 2017-2031
  • Figure 48: Europe Antihypertensive Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 49: Europe Antihypertensive Drugs Market Value Share Analysis, by Therapy Type, 2017-2031
  • Figure 50: Europe Antihypertensive Drugs Market Attractiveness Analysis, by Therapy Type, 2017-2031
  • Figure 51: Europe Antihypertensive Drugs Market Value Share Analysis, by Type, 2017-2031
  • Figure 52: Europe Antihypertensive Drugs Market Attractiveness Analysis, by Type, 2017-2031
  • Figure 53: Europe Antihypertensive Drugs Market Value Share Analysis, by Medication Type, 2017-2031
  • Figure 54: Europe Antihypertensive Drugs Market Attractiveness Analysis, by Medication Type, 2017-2031
  • Figure 55: Europe Antihypertensive Drugs Market Value Share Analysis, by Distribution Channel, 2017-2031
  • Figure 56: Europe Antihypertensive Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031
  • Figure 57: Asia Pacific Antihypertensive Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 58: Asia Pacific Antihypertensive Drugs Market Value Share Analysis, by Country/Sub-region, 2017-2031
  • Figure 59: Asia Pacific Antihypertensive Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 60: Asia Pacific Antihypertensive Drugs Market Value Share Analysis, by Therapy Type, 2017-2031
  • Figure 61: Asia Pacific Antihypertensive Drugs Market Attractiveness Analysis, by Therapy Type, 2017-2031
  • Figure 63: Asia Pacific Antihypertensive Drugs Market Attractiveness Analysis, by Type, 2017-2031
  • Figure 64: Asia Pacific Antihypertensive Drugs Market Value Share Analysis, by Medication Type, 2017-2031
  • Figure 65: Asia Pacific Antihypertensive Drugs Market Attractiveness Analysis, by Medication Type, 2017-2031
  • Figure 66: Asia Pacific Antihypertensive Drugs Market Value Share Analysis, by Distribution Channel, 2017-2031
  • Figure 67: Asia Pacific Antihypertensive Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031
  • Figure 68: Latin America Antihypertensive Drugs Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031
  • Figure 69: Latin America Antihypertensive Drugs Market Value Share Analysis, by Country/Sub-region, 2017-2031
  • Figure 70: Latin America Antihypertensive Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 71: Latin America Antihypertensive Drugs Market Value Share Analysis, by Therapy Type, 2017-2031
  • Figure 72: Latin America Antihypertensive Drugs Market Attractiveness Analysis, by Therapy Type, 2017-2031
  • Figure 73: Latin America Antihypertensive Drugs Market Value Share Analysis, by Type, 2017-2031
  • Figure 74: Latin America Antihypertensive Drugs Market Attractiveness Analysis, by Type, 2017-2031
  • Figure 75: Latin America Antihypertensive Drugs Market Value Share Analysis, by Medication Type, 2017-2031
  • Figure 76: Latin America Antihypertensive Drugs Market Attractiveness Analysis, by Medication Type, 2017-2031
  • Figure 77: Latin America Antihypertensive Drugs Market Value Share Analysis, by Distribution Channel, 2017-2031
  • Figure 78: Latin America Antihypertensive Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031
  • Figure 79: Middle East & Africa Antihypertensive Drugs Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031
  • Figure 80: Middle East & Africa Antihypertensive Drugs Market Value Share Analysis, by Country/Sub-region, 2017-2031
  • Figure 81: Middle East & Africa Antihypertensive Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 82: Middle East & Africa Antihypertensive Drugs Market Value Share Analysis, by Therapy Type, 2017-2031
  • Figure 83: Middle East & Africa Antihypertensive Drugs Market Attractiveness Analysis, by Therapy Type, 2017-2031
  • Figure 84: Middle East & Africa Antihypertensive Drugs Market Value Share Analysis, by Type, 2017-2031
  • Figure 85: Middle East & Africa Antihypertensive Drugs Market Attractiveness Analysis, by Type, 2017-2031
  • Figure 86: Middle East & Africa Antihypertensive Drugs Market Value Share Analysis, by Medication Type, 2017-2031
  • Figure 87: Middle East & Africa Antihypertensive Drugs Market Attractiveness Analysis, by Medication Type, 2017-2031
  • Figure 88: Middle East & Africa Antihypertensive Drugs Market Value Share Analysis, by Distribution Channel, 2017-2031
  • Figure 89: Middle East & Africa Antihypertensive Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031
  • Figure 78: Latin America Antihypertensive Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031
  • Figure 79: Middle East & Africa Antihypertensive Drugs Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031
目次
Product Code: TMRGL7718

The report provides revenue of the global antihypertensive drugs market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global antihypertensive drugs market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the antihypertensive drugs market.

The report delves into the competitive landscape of the global antihypertensive drugs market. Key players operating in the global antihypertensive drugs market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global antihypertensive drugs market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Antihypertensive Drugs Market

4. Market Overview

  • 4.1. Introduction
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Antihypertensive Drugs Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Bn)

5. Market Outlook

  • 5.1. Key Industry Developments
  • 5.2. Impact scenario
  • 5.3. New product developments

6. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Therapy Type

  • 6.1. Introduction & Definition
  • 6.2. Global Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031
    • 6.2.1. Diuretics
      • 6.2.1.1. Thiazide diuretics
      • 6.2.1.2. Loop diuretics
      • 6.2.1.3. Potassium-sparing diuretics
    • 6.2.2. Angiotensin Converting Enzyme Inhibitors
    • 6.2.3. Angiotensin Receptor Blockers
    • 6.2.4. Beta-blockers
      • 6.2.4.1. Beta-1 Selective
      • 6.2.4.2. Intrinsic Sympathomimetic
    • 6.2.5. Vasodilators
    • 6.2.6. Calcium Channel Blockers
    • 6.2.7. Renin Inhibitors
    • 6.2.8. Alpha-blockers
    • 6.2.9. Others
  • 6.3. Global Antihypertensive Drugs Market Attractiveness, by Therapy Type

7. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Type

  • 7.1. Introduction & Definition
  • 7.2. Global Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
    • 7.2.1. Primary Hypertension
    • 7.2.2. Secondary Hypertension
  • 7.3. Global Antihypertensive Drugs Market Attractiveness, by Type

8. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Medication Type

  • 8.1. Introduction
  • 8.2. Global Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
    • 8.2.1. Monotherapy
    • 8.2.2. Combination Therapy
    • 8.2.3. Fixed Dose Combinations
  • 8.3. Global Antihypertensive Drugs Market Attractiveness, by Medication Type

9. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Global Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031
    • 9.2.1. Retail Pharmacies
    • 9.2.2. Hospital Pharmacies
    • 9.2.3. Online Pharmacies
    • 9.2.4. Others
  • 9.3. Global Antihypertensive Drugs Market Attractiveness, by Distribution Channel

10. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Region

  • 10.1. Introduction
  • 10.2. Antihypertensive Drugs Market Value Forecast, by Region, 2017-2031
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Global Antihypertensive Drugs Market Attractiveness, by Region

11. North America Antihypertensive Drugs Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. North America Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031
    • 11.2.1. Diuretics
      • 11.2.1.1. Thiazide diuretics
      • 11.2.1.2. Loop diuretics
      • 11.2.1.3. Potassium-sparing diuretics
    • 11.2.2. Angiotensin Converting Enzyme Inhibitors
    • 11.2.3. Angiotensin Receptor Blockers
    • 11.2.4. Beta-blockers
      • 11.2.4.1. Beta-1 Selective
      • 11.2.4.2. Intrinsic Sympathomimetic
    • 11.2.5. Vasodilators
    • 11.2.6. Calcium Channel Blockers
    • 11.2.7. Renin Inhibitors
    • 11.2.8. Alpha-blockers
    • 11.2.9. Others
  • 11.3. North America Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
    • 11.3.1. Primary Hypertension
    • 11.3.2. Secondary Hypertension
  • 11.4. North America Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
    • 11.4.1. Monotherapy
    • 11.4.2. Combination Therapy
    • 11.4.3. Fixed Dose Combinations
    • 11.4.4. Others
  • 11.5. North America Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.5.1. Retail Pharmacies
    • 11.5.2. Hospital Pharmacies
    • 11.5.3. Online Pharmacies
    • 11.5.4. Others
  • 11.6. North America Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. North America Antihypertensive Drugs Market Attractiveness Analysis
    • 11.7.1. By Therapy Type
    • 11.7.2. By Type
    • 11.7.3. By Medication Type
    • 11.7.4. By Distribution Channel
    • 11.7.5. By Country/Sub-region

12. Europe Antihypertensive Drugs Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Europe Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031
    • 12.2.1. Diuretics
      • 12.2.1.1. Thiazide diuretics
      • 12.2.1.2. Loop diuretics
      • 12.2.1.3. Potassium-sparing diuretics
    • 12.2.2. Angiotensin Converting Enzyme Inhibitors
    • 12.2.3. Angiotensin Receptor Blockers
    • 12.2.4. Beta-blockers
      • 12.2.4.1. Beta-1 Selective
      • 12.2.4.2. Intrinsic Sympathomimetic
    • 12.2.5. Vasodilators
    • 12.2.6. Calcium Channel Blockers
    • 12.2.7. Renin Inhibitors
    • 12.2.8. Alpha-blockers
    • 12.2.9. Others
  • 12.3. Europe Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
    • 12.3.1. Primary Hypertension
    • 12.3.2. Secondary Hypertension
  • 12.4. Europe Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
    • 12.4.1. Monotherapy
    • 12.4.2. Combination Therapy
    • 12.4.3. Fixed Dose Combinations
    • 12.4.4. Others
  • 12.5. Europe Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.5.1. Retail Pharmacies
    • 12.5.2. Hospital Pharmacies
    • 12.5.3. Online Pharmacies
    • 12.5.4. Others
  • 12.6. Europe Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Spain
    • 12.6.5. Italy
    • 12.6.6. Rest of Europe
  • 12.7. Europe Antihypertensive Drugs Market Attractiveness Analysis
    • 12.7.1. By Therapy Type
    • 12.7.2. By Type
    • 12.7.3. By Medication Type
    • 12.7.4. By Distribution Channel
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Antihypertensive Drugs Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031
    • 13.2.1. Diuretics
      • 13.2.1.1. Thiazide diuretics
      • 13.2.1.2. Loop diuretics
      • 13.2.1.3. Potassium-sparing diuretics
    • 13.2.2. Angiotensin Converting Enzyme Inhibitors
    • 13.2.3. Angiotensin Receptor Blockers
    • 13.2.4. Beta-blockers
      • 13.2.4.1. Beta-1 Selective
      • 13.2.4.2. Intrinsic Sympathomimetic
    • 13.2.5. Vasodilators
    • 13.2.6. Calcium Channel Blockers
    • 13.2.7. Renin Inhibitors
    • 13.2.8. Alpha-blockers
    • 13.2.9. Others
  • 13.3. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
    • 13.3.1. Primary Hypertension
    • 13.3.2. Secondary Hypertension
  • 13.4. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
    • 13.4.1. Monotherapy
    • 13.4.2. Combination Therapy
    • 13.4.3. Fixed Dose Combinations
    • 13.4.4. Others
  • 13.5. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.5.1. Retail Pharmacies
    • 13.5.2. Hospital Pharmacies
    • 13.5.3. Online Pharmacies
    • 13.5.4. Others
  • 13.6. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. Japan
    • 13.6.2. China
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Asia Pacific Antihypertensive Drugs Market Attractiveness Analysis
    • 13.7.1. By Therapy Type
    • 13.7.2. By Type
    • 13.7.3. By Medication Type
    • 13.7.4. By Distribution Channel
    • 13.7.5. By Country/Sub-region

14. Latin America Antihypertensive Drugs Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Latin America Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031
    • 14.2.1. Diuretics
      • 14.2.1.1. Thiazide diuretics
      • 14.2.1.2. Loop diuretics
      • 14.2.1.3. Potassium-sparing diuretics
    • 14.2.2. Angiotensin Converting Enzyme Inhibitors
    • 14.2.3. Angiotensin Receptor Blockers
    • 14.2.4. Beta-blockers
      • 14.2.4.1. Beta-1 Selective
      • 14.2.4.2. Intrinsic Sympathomimetic
    • 14.2.5. Vasodilators
    • 14.2.6. Calcium Channel Blockers
    • 14.2.7. Renin Inhibitors
    • 14.2.8. Alpha-blockers
    • 14.2.9. Others
  • 14.3. Latin America Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
    • 14.3.1. Primary Hypertension
    • 14.3.2. Secondary Hypertension
  • 14.4. Latin America Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
    • 14.4.1. Monotherapy
    • 14.4.2. Combination Therapy
      • 14.4.2.1. Thiazide diuretics
      • 14.4.2.2. Loop diuretics
      • 14.4.2.3. Potassium-sparing diuretics
    • 14.4.3. Angiotensin Converting Enzyme Inhibitors
    • 14.4.4. Angiotensin Receptor Blockers
    • 14.4.5. Beta-blockers
      • 14.4.5.1. Beta-1 Selective
      • 14.4.5.2. Intrinsic Sympathomimetic
    • 14.4.6. Vasodilators
    • 14.4.7. Calcium Channel Blockers
    • 14.4.8. Renin Inhibitors
    • 14.4.9. Alpha-blockers
    • 14.4.10. Others
  • 14.5. Latin America Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
    • 14.5.1. Primary Hypertension
    • 14.5.2. Secondary Hypertension
  • 14.6. Latin America Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
    • 14.6.1. Monotherapy
    • 14.6.2. Combination Therapy
    • 14.6.3. Fixed Dose Combinations
    • 14.6.4. Others
  • 14.7. Latin America Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.7.1. Retail Pharmacies
    • 14.7.2. Hospital Pharmacies
    • 14.7.3. Online Pharmacies
    • 14.7.4. Others
  • 14.8. Latin America Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.8.1. Brazil
    • 14.8.2. Mexico
    • 14.8.3. Rest of Latin America
  • 14.9. Latin America Antihypertensive Drugs Market Attractiveness Analysis
    • 14.9.1. By Therapy Type
    • 14.9.2. By Type
    • 14.9.3. By Medication Type
    • 14.9.4. By Distribution Channel
    • 14.9.5. By Country/Sub-region

15. Middle East & Africa Antihypertensive Drugs Market Analysis and Forecast

  • 15.1. Introduction
  • 15.2. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031
    • 15.2.1. Diuretics
      • 15.2.1.1. Thiazide diuretics
      • 15.2.1.2. Loop diuretics
      • 15.2.1.3. Potassium-sparing diuretics
    • 15.2.2. Angiotensin Converting Enzyme Inhibitors
    • 15.2.3. Angiotensin Receptor Blockers
    • 15.2.4. Beta-blockers
      • 15.2.4.1. Beta-1 Selective
      • 15.2.4.2. Intrinsic Sympathomimetic
    • 15.2.5. Vasodilators
    • 15.2.6. Calcium Channel Blockers
    • 15.2.7. Renin Inhibitors
    • 15.2.8. Alpha-blockers
    • 15.2.9. Others
  • 15.3. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
    • 15.3.1. Primary Hypertension
    • 15.3.2. Secondary Hypertension
  • 15.4. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
    • 15.4.1. Monotherapy
    • 15.4.2. Combination Therapy
    • 15.4.3. Fixed Dose Combinations
    • 15.4.4. Others
  • 15.5. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031
    • 15.5.1. Retail Pharmacies
    • 15.5.2. Hospital Pharmacies
    • 15.5.3. Online Pharmacies
    • 15.5.4. Others
  • 15.6. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Israel
    • 15.6.4. Rest of Middle East & Africa
  • 15.7. Middle East & Africa Antihypertensive Drugs Market Attractiveness Analysis
    • 15.7.1. By Therapy Type
    • 15.7.2. By Type
    • 15.7.3. By Medication Type
    • 15.7.4. By Distribution Channel
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (by tier and size of companies)
  • 16.2. Company Profiles
    • 16.2.1. Pfizer, Inc.
      • 16.2.1.1. Company Description
      • 16.2.1.2. Business Overview
      • 16.2.1.3. Financial Overview
      • 16.2.1.4. Strategic Overview
      • 16.2.1.5. SWOT Analysis
    • 16.2.2. Sanofi S.A
      • 16.2.2.1. Company Description
      • 16.2.2.2. Business Overview
      • 16.2.2.3. Financial Overview
      • 16.2.2.4. Strategic Overview
      • 16.2.2.5. SWOT Analysis
    • 16.2.3. Novartis AG
      • 16.2.3.1. Company Description
      • 16.2.3.2. Business Overview
      • 16.2.3.3. Financial Overview
      • 16.2.3.4. Strategic Overview
      • 16.2.3.5. SWOT Analysis
    • 16.2.4. Boehringer Ingelheim GmbH
      • 16.2.4.1. Company Description
      • 16.2.4.2. Business Overview
      • 16.2.4.3. Financial Overview
      • 16.2.4.4. Strategic Overview
      • 16.2.4.5. SWOT Analysis
    • 16.2.5. Actelion Ltd. (Johnson & Johnson Services, Inc.)
      • 16.2.5.1. Company Description
      • 16.2.5.2. Business Overview
      • 16.2.5.3. Financial Overview
      • 16.2.5.4. Strategic Overview
      • 16.2.5.5. SWOT Analysis
    • 16.2.6. F. Hoffmann-La Roche Ltd.
      • 16.2.6.1. Company Description
      • 16.2.6.2. Business Overview
      • 16.2.6.3. Financial Overview
      • 16.2.6.4. Strategic Overview
      • 16.2.6.5. SWOT Analysis
    • 16.2.7. Bayer AG
      • 16.2.7.1. Company Description
      • 16.2.7.2. Business Overview
      • 16.2.7.3. Financial Overview
      • 16.2.7.4. Strategic Overview
      • 16.2.7.5. SWOT Analysis
    • 16.2.8. Daiichi Sankyo Company, Limited
      • 16.2.8.1. Company Description
      • 16.2.8.2. Business Overview
      • 16.2.8.3. Financial Overview
      • 16.2.8.4. Strategic Overview
      • 16.2.8.5. SWOT Analysis
    • 16.2.9. Takeda Pharmaceutical Company Limited
      • 16.2.9.1. Company Description
      • 16.2.9.2. Business Overview
      • 16.2.9.3. Financial Overview
      • 16.2.9.4. Strategic Overview
      • 16.2.9.5. SWOT Analysis